UroGen Pharma Ltd. (URGN) FY2026 Q2 P&L / Income Statement

UroGen Pharma Ltd. (URGN) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

72,456,000 US dollars

Cost of revenue

6,572,000 US dollars

Gross profit

65,884,000 US dollars

Operating expenses (calculated)

65,773,000 US dollars

Operating income (loss)

111,000 US dollars

Other income (expense), net (calculated)

negative 8,833,000 US dollars

Loss before income taxes

negative 8,722,000 US dollars

Income tax expense

5,629,000 US dollars

Net loss

negative 14,351,000 US dollars

Jelmyto

22,028,000 US dollars

Zusduri

50,429,000 US dollars

Selling, general and administrative expenses

48,437,000 US dollars

Research and development expenses

17,336,000 US dollars

Revenue before reconciliation (calculated)

72,457,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.

Components above reported revenue (calculated)

negative 1,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
• Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.